NASDAQ · WST
Healthcare · Medical - Instruments & Supplies
$408.78
Down-$5.44 (-1.33%)
Updated Nov 5, 2026, 4:30 PM
SID Score
6.7/10
Composite research score
Smart Money
58/100
Neutral
Price performance · WST
1M range · 0 trading sessions · Daily adjusted prices
WST does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning WST.
Company
Market Activity
Research & News
WST research
Company profile and research snapshot.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | TD Cowen | Buy | — |
| Oct 30, 2026 | Barclays | Overweight | — |
| Oct 30, 2026 | Evercore ISI Group | Outperform | — |
| Oct 30, 2026 | Citigroup | Buy | — |
| Oct 13, 2026 | TD Cowen | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 31, 2026
West Pharmaceutical Services (NYSE:WST) reported third-quarter results that exceeded its expectations, driven by continued demand for high-value product components, including those used in GLP-1 therapies and biologics. The company raised its full-year revenue and adjusted earnings outlook following
Benzinga · Oct 30, 2026
Citigroup analyst Joanne Wuensch maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $412 to $494.
Benzinga · Oct 30, 2026
TD Cowen analyst Brendan Smith maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $420 to $500.
Benzinga · Oct 30, 2026
Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $440 to $500.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning WST.
